Classifying and predicting glomerulosclerosis using a proteomics approach

• US 20060223122A1
• Filed: 03/08/2006
• Published: 10/05/2006
• Est. Priority Date: 03/08/2005
• Status: Abandoned Application

• Current Assignee: Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: Fogo, Agnes, Caprioli, Richard
• Application Number:
  US11/371,355
• Publication Number:
  US 20060223122A1
• Time in Patent Office: Days
• US Class Current: 435/7.200
• CPC Class Codes: G01N 2800/347 Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
• CPC Class Codes: G01N 33/5082 Supracellular entities, e.g. tissue, organisms
• CPC Class Codes: G01N 33/6851 Methods of protein analysis involving laser desorption ionisation mass spectrometry
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention provides for a proteomic approach to classifying glomerular tissue as normal, non-sclerotic or sclerotic. In particular, the proteomic approach may employ laser capture microdissection followed by MALDI-TOF. A particular target of interest that is highly relevant in distinguishing such tissues is thymosin β4.

Claims

1. A method of classifying glomerular tissue as normal, non-sclerotic or sclerotic comprising:

(a) obtaining a glomerular tissue sample;

(b) analyzing protein content of said tissue sample;

(c) comparing the protein content of said tissue sample with a predetermined standard; and

(d) classifying said glomerular tissue as normal, non-sclerotic or sclerotic.

2. The method of claim 1, wherein said glomerular tissue is classified as focal segmental glomerulosclerotic.

3. The method of claim 1, wherein analyzing protein content comprises assessing proteomic patterns.

4. The method of claim 3, wherein analyzing comprises mass spectrometry.

5. The method of claim 3, wherein analyzing comprises immunohistochemistry.

6. The method of claim 3, wherein analyzing comprises 2-D gel electrophoresis.

7. The method of claim 1, wherein analyzing protein content comprises assessing thymosin β

4 expression.

8. The method of claim 7, wherein analyzing comprises mass spectrometry.

9. The method of claim 7, wherein analyzing comprises immunohistochemistry.

10. The method of claim 1, wherein analyzing protein content comprises laser capture microdissection coupled with matrix-assisted laser desporption/ionization time-of-flight mass spectrometry.

11. The method of claim 1, wherein analyzing comprises assessing expression of one or more proteins having molecular weights of 4222 Daltons, 5485 Daltons, 7018 Daltons and 12,131 Daltons.

12. The method of claim 11, wherein analyzing comprises mass spectrometry.

13. The method of claim 1, wherein said sample is from a mammal.

14. The method of claim 1, wherein said sample is from a human.

15. The method of claim 1, further comprising making a medical treatment decision based on said classification.

16. The method of claim 7, further comprising analyzing assessing expression of one or more proteins having molecular weights of 4222 Daltons, 5485 Daltons, 7018 Daltons and 12,131 Daltons.

17. A method of identifying a marker in a glomerular tissue comprising:

(a) obtaining a diseased glomerular tissue sample;

(b) analyzing protein content of said tissue sample;

(c) comparing the protein content of said tissue sample with a normal glomerular tissue sample; and

(d) identifying a marker in said diseased glomerular tissue sampel that is as normal, non-sclerotic or sclerotic.

18. The method of claim 17, wherein analyzing comprises mass spectrometry, immunohistochemistry or 2-D gel electrophoresis.